Intralesional Chemotherapy (IC): Cisplatin + Epinephrine

Abroad (travel likely)RecruitingPHASE2

Conditions

Laryngeal Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Miami, Miami, Florida, United States
Contact: Study coordinator (David E Rosow, MD) · DRosow@med.miami.edu · +1 (305) 2432587
Contact: Principal Investigator (David E Rosow, MD)

Study leads

David Rosow, MD
Principal Investigator
University of Miami

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma · Recurrent Hypopharyngeal Squamous Cell Carcinoma · Recurrent Laryngeal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Little Rock, United States

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Locally Recurrent Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Tucson, United States · Tucson, United States

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Abroad (travel likely)RecruitingPHASE2

Gilbert, United States · Peoria, United States

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Pittsburgh, United States